Myriad Genetics (NASDAQ:MYGN) Issues FY 2025 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.070-0.110 for the period, compared to the consensus estimate of 0.060. The company issued revenue guidance of $840.0 million-$860.0 million, compared to the consensus revenue estimate of $863.0 million.

Myriad Genetics Stock Performance

MYGN opened at $10.18 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $929.53 million, a PE ratio of -7.83 and a beta of 1.79. The firm’s 50-day moving average price is $13.02 and its 200 day moving average price is $18.55. Myriad Genetics has a twelve month low of $9.76 and a twelve month high of $29.30.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. The firm had revenue of $210.60 million during the quarter, compared to analysts’ expectations of $210.35 million. During the same period in the prior year, the company posted ($0.12) earnings per share. As a group, sell-side analysts expect that Myriad Genetics will post -0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on MYGN shares. UBS Group cut their target price on shares of Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating for the company in a research report on Tuesday, February 25th. Leerink Partners downgraded shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $30.00 to $21.00 in a research note on Monday, December 9th. StockNews.com cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Saturday, March 1st. Stephens reissued an “equal weight” rating and set a $20.00 target price on shares of Myriad Genetics in a report on Thursday, January 16th. Finally, Piper Sandler lowered their price target on shares of Myriad Genetics from $14.00 to $11.50 and set a “neutral” rating for the company in a research report on Tuesday. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Myriad Genetics currently has a consensus rating of “Hold” and an average price target of $21.82.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.